Baker McKenzie acted as lead counsel to Takeda in connection with its worldwide license and collaboration agreement with Protagonist Therapeutics, Inc., for the development and commercialization of rusfertide, an investigational injectable hepcidin mimetic peptide of the natural hormone hepcidin, currently in a pivotal Phase 3 trial, VERIFY, for the treatment of Polycythemia Vera, a rare chronic blood disorder. 

Led by Randy Sunberg, Chair of Baker McKenzie's North America Healthcare & Life Sciences Practice, the Baker McKenzie team included Partners Nandu Machiraju and Xin Tao and Associates Devin Muntz, Anat Polyachenko, and Daniel Duk-ki Moon. 

As one of the first law firms to advise life sciences companies on their global expansion 60 years ago, Baker McKenzie's deep knowledge in the industry, honed over the decades, is rooted in the Firm's corporate DNA. Baker's Healthcare & Life Sciences group is one of the largest of any international law firm comprising more than 800 lawyers in 45 countries. The Firm has been recognized for their work in the industry, including receiving a 2022 Impact Deal of the Year by LMG Life Sciences for their representation of Takeda in its $3.6 billion collaboration with Poseida Therapeutics.

Baker McKenzie is a transactional powerhouse, with more than 2,500 deal lawyers in 45 jurisdictions offering pragmatic counsel in the areas most critical for clients. The Firm excels in complex transactions and cross-border deals – over 65% of the deals are multi-jurisdictional. The teams are global and local, combining money-market sophistication with local excellence.
Explore Our Newsroom